3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
6
Dermatologic
5
Head & Neck
4
Thoracic
2
Sarcoma
2
Gastrointestinal
2
Breast
2
Other solid neoplasm
1
Other hematologic neoplasm
1
Lymphoid
1
CNS
1
Conditions
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Recurrence
1
Neuroblastoma
1
Neoplasms
1
Melanoma
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Glioma
1
Ependymoma
1
Interventions
Cyclophosphamide
296
Cytarabine
261
fludarabine phosphate
218
Rituximab
195
fludarabine
182
Methotrexate
152
Whole-Body Irradiation
140
Mycophenolic Acid
124
Azacitidine
122
Tacrolimus
116
Busulfan
110
Filgrastim
104
Granulocyte Colony-Stimulating Factor
98
Etoposide
91
Peripheral Blood Stem Cell Transplantation
90
Dexamethasone
89
Vincristine
88
Melphalan
80
Cyclosporine
74
Lenalidomide
73
Daunorubicin
70
Decitabine
69
Clofarabine
69
Antilymphocyte Serum
67
Calcium Dobesilate
61
venetoclax
60
Doxorubicin
58
Imatinib Mesylate
57
Alemtuzumab
56
ibrutinib
55
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
bempegaldesleukin
×
Other hematologic neoplasm
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts